EssilorLuxottica's Earnings Credibility in Focus as Hearing-Aid Glasses Debut and Analysts Diverge
Published on 09/25/2026 at 06:51 | Editorial boerse-global.de
EssilorLuxottica used a single week to roll out hearing-aid eyewear, a third generation of AI-powered frames, and fresh clinical evidence for its myopia lenses — yet investors greeted the flurry of announcements by marking the stock down 2.9% to EUR 145.45. The muted reception underscores a widening gap between the company's product momentum and the market's confidence in near-term profitability.
Nuance Audio Plus and a Broader Frame Portfolio
The centerpiece of Thursday's launch was Nuance Audio Plus, a hearing-assist frame aimed at users who need amplification but prefer to avoid conventional medical devices. According to the company, the model delivers improved acoustics, longer battery life, and a wider selection of frame styles. Sales begin September 30 in Canada, with a recommended retail price starting at $1,149.
Alongside the hearing product, EssilorLuxottica and Meta Platforms unveiled the Ray-Ban Meta Gen 3 and a camera-free variant, Ray-Ban Meta Audio. The third generation starts at $449, while the audio-only model is slated to reach shelves on October 13 from $349. Additional designs and lower-priced options round out the range.
The dual push into hearing and AI features is designed to capture users who might otherwise shun traditional hearing aids or who want digital assistance woven into everyday eyewear.
Geographic Rollout and the 100-Model Threshold
Distribution is expanding in parallel. Media reports indicate the AI glasses will reach ten more countries, among them Poland, Portugal, Israel, South Africa, and several Asian markets including Indonesia, Thailand, Malaysia, New Zealand, the Philippines, and Hong Kong. By year-end, the lineup is expected to surpass 100 frame variants.
Should investors sell immediately? Or is it worth buying EssilorLuxottica?
The company's market capitalization stands at EUR 66.29 billion.
Clinical Validation for Stellest 2.0
Away from the technology partnership, EssilorLuxottica disclosed interim results Tuesday from its medical core. A clinical trial conducted in China on Essilor Stellest 2.0 lenses for nearsighted children showed measurable treatment effects after six months.
Relative to standard single-vision lenses, the glasses slowed myopia progression by an average of 0.51 diopters and curbed axial elongation of the eye by 0.21 millimeters.
Analysts Split on the Outlook
Wall Street's response has been anything but uniform. RBC Capital Markets cut its price target on Tuesday to EUR 190 from EUR 230 while keeping an "Outperform" rating, citing expectations of normalized revenue growth in the third quarter. Jefferies, on the same day, reaffirmed a "Buy" rating and a EUR 250 target following discussions with Paris-based ophthalmologist Aurore Muselier-Mathieu. Citi noted that the newly introduced products should sustain momentum in connected eyewear.
Those endorsements have done little to dispel investor caution. Traders acknowledge that the technology build-out is proceeding on schedule, but many remain unconvinced that the category can deliver meaningful earnings in the short term.
With the shares down 46% year-to-date, the burden of proof now rests on coming quarters — whether a wider model range and new sales territories can translate into a durable recovery.
Ad
EssilorLuxottica Stock: New Analysis - 25 September
Fresh EssilorLuxottica information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
